Arix Bioscience brings in new non-executive directors


Arix Bioscience PLC (LON:ARIX) said James Noble and Axel Wieandt will be joining the board as non-executive directors (NEDs) effective April 1.

The biotech-focused venture capital firm said Noble has “extensive experience in the biotech industry” and currently serves as lead independent director and deputy chairman of pharmaceutical firm GW Pharmaceuticals, chairman of Swedish mental illness therapy specialist Orexo AB, and a director of T-cell therapeutics group Adaptimmune Therapeutics.

READ: Arix Bioscience says portfolio company Autolus seeks US$100mln IPO

Wieandt, meanwhile, is a senior financial services professional with expertise in banking, financial technology and finance, having previously served as head of corporate development and global head of corporate investments at Deutsche Bank. He currently advises US and European private equity firms, venture capital funds and real estate companies on their investment and value creation strategies as well as acting as a senior advisor to several fintech and pharma companies.

The company also said that NED Mark Breuer will step down on April 1 after serving on the board for two years, while Giles Kerr has been appointed as senior independent director alongside his current role as chairman of the audit committee with immediate effect.

“We are delighted to announce that James and Axel are joining the Arix board. They bring a wealth of experience that will be crucial in shaping the future strategy and success of the company. On behalf of the board, I would like to thank Mark Breuer for the commitment and invaluable support he has shown to the company over the last two years”, Arix executive chairman Naseem Amin said in a statement.

The company’s shares were 0.6% lower at 194.9p in early deals on Thursday.


Please enter your comment!
Please enter your name here